Nissen Analysis Underscores Link Between Avandia, Cardiovascular Events

Drug Industry Daily
A A
On the heels of an advisory committee meeting next month on whether GlaxoSmithKline’s (GSK) Avandia should stay on the market, a new meta-analysis of the diabetes drug has added more evidence of an unfavorable benefit-to-risk ratio.

To View This Article:

Login

Subscribe To Drug Industry Daily